Emcure Pharmaceuticals Ltd recently announced the launch of its new oncology plant at Pune. The facility is spread over an area of 70,000 sq ft. Emcure's total investment for the oncology formulations facility and API facility exceeded $ 25 million.

Committed to offer the latest in cancer therapy in India and worldwide, the oncology division will manufacture and market the products at an affordable cost. The facility is designed to comply with the requirements of global regulatory authorities and is based on the latest isolation technology that will ensure protection of the products, operating personnel and environment.

The company also inaugurated its subsidiary Gennova Biopharmaceuticals' Malaria Vaccine Facility at Pune that will develop and manufacture malaria vaccine candidates for worldwide clinical trials.
The new facilities were inaugurated by Sharad Pawar, minister for agriculture, Government of India. Satish Mehta, CEO, Emcure Pharmaceuticals, said, ''The oncology market in India is estimated at
Rs 400 crore and is growing at the rate of 30 per cent. We aim to achieve 15-20 per cent market share in this segment within the next five years.''